文献速递神经肿瘤

IDH野生型胶质母细胞瘤中MGMT启动子甲基化状态相关的分子差异

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
PubMed 文献 · Neuro Oncol · 2018-01-01

该研究分析了1095例原发和92例进展期IDH野生型胶质母细胞瘤的拷贝数变异和甲基化谱,并整合TCGA与CGGA的突变和RNA表达数据。结果发现,在未治疗肿瘤中MGMT启动子甲基化状态并不定义分子上独特的亚群,但进展期mMGMT肿瘤及短生存期mMGMT患者的肿瘤倾向于具有更不利的分子特征。

要点

  • 未治疗IDH野生型胶质母细胞瘤中,MGMT启动子甲基化与未甲基化肿瘤在拷贝数变异和特定基因突变上无差异,但mMGMT肿瘤突变计数更高。
  • 研究识别出3个甲基化簇,簇1平均甲基化最高且富集mMGMT肿瘤,包含GBX2在内的17个基因在mMGMT肿瘤中高甲基化且mRNA下调。
  • 进展期mMGMT肿瘤富集PDGFRA和GLI2扩增,且mMGMT肿瘤在进展时获得PDGFRA扩增,而uMGMT伴PDGFRA扩增的肿瘤常丢失该扩增。

核心结论

  • MGMT启动子甲基化状态在未治疗胶质母细胞瘤中并不定义分子上独特的亚群,但进展期mMGMT肿瘤及短生存期mMGMT患者的肿瘤倾向于具有更不利的分子谱。

研究设计与样本

  • 研究分析了1095例原发和92例进展期IDH野生型胶质母细胞瘤的拷贝数变异和甲基化谱,包括49例患者的配对样本。
  • 还分析了182例TCGA胶质母细胞瘤样本的DNA突变数据,以及107例TCGA和55例中国胶质瘤基因组图谱样本的RNA表达数据。

主要发现

  • 在未治疗胶质母细胞瘤中,mMGMT和uMGMT肿瘤在拷贝数变异或特定基因突变上无差异,但mMGMT肿瘤突变计数更高。
  • 识别出3个甲基化簇,簇1平均甲基化最高且富集mMGMT肿瘤;包括GBX2在内的17个基因在mMGMT肿瘤中高甲基化且mRNA下调。
  • 在进展期胶质母细胞瘤中,PDGFRA和GLI2扩增在mMGMT肿瘤中富集;mMGMT肿瘤在进展时获得PDGFRA扩增,而uMGMT伴PDGFRA扩增的肿瘤常丢失该扩增。
  • 生存期<6个月且mMGMT的患者较生存期>12个月者,EGFR扩增频率更低、TP53突变频率更高、TNF-NFκB通路激活更高。

关键数值与推荐

  • 在未治疗胶质母细胞瘤中,mMGMT与uMGMT肿瘤在拷贝数变异或特定基因突变上无差异,但mMGMT肿瘤突变计数更高。
  • 识别出3个甲基化簇,簇1平均甲基化最高且富集mMGMT肿瘤。
  • 包括GBX2在内的17个基因在mMGMT肿瘤中高甲基化且mRNA下调。
  • 在进展期胶质母细胞瘤中,PDGFRA和GLI2扩增在mMGMT肿瘤中富集。
  • 生存期<6个月且mMGMT的患者较生存期>12个月者,EGFR扩增频率更低、TP53突变频率更高、TNF-NFκB通路激活更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma. We investigated whether this marker furthermore defines a molecularly distinct tumor subtype with clinically different outcome. METHODS: We analyzed copy number variation (CNV) and methylation profiles of 1095 primary and 92 progressive isocitrate dehydrogenase wildtype glioblastomas, including paired samples from 49 patients. DNA mutation data from 182 glioblastoma samples of The Cancer Genome Atlas (TCGA) and RNA expression from 107 TCGA and 55 Chinese Glioma Genome Atlas samples were analyzed. RESULTS: Among untreated glioblastomas, MGMT promoter methylated (mMGMT) and unmethylated (uMGMT) tumors did not show different CNV or specific gene mutations, but a higher mutation count in mMGMT tumors. We identified 3 methylation clusters. Cluster 1 showed the highest average methylation and was enriched for mMGMT tumors. Seventeen genes including gastrulation brain homeobox 2 (GBX2) were found to be hypermethylated and downregulated on the mRNA level in mMGMT tumors. In progressive glioblastomas, platelet derived growth factor receptor alpha (PDGFRA) and GLI2 amplifications were enriched in mMGMT tumors. Methylated MGMT tumors gain PDGFRA amplification of PDGFRA, whereas uMGMT tumors with amplified PDGFRA frequently lose this amplification upon progression. Glioblastoma patients surviving <6 months and with mMGMT harbored less frequent epidermal growth factor receptor (EGFR) amplifications, more frequent TP53 mutations, and a higher tumor necrosis factor-nuclear factor-kappaB (TNF-NFκB) pathway activation compared with patients surviving >12 months. CONCLUSIONS: MGMT promoter methylation status does not define a molecularly distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT glioblastomas and mMGMT tumors of patients with short survival tend to have more unfavorable molecular profiles.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kessler T, Sahm F, Sadik A, et al. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro Oncol. 2018. PMID: 29016808. doi:10.1093/neuonc/nox160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。